Non-Invasive Biomarkers in Prostate Cancer Disease Management

Overseen By Julio Pow-Sang, MD

Age: 18+

Sex: Male

Trial Phase: Academic

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

500 Participants Needed

Trial Summary

What is the purpose of this trial?

This study is an observational retrospective/ prospective study with diagnosed low/intermediate risk (no-surgery) \& high risk (surgery) prostate cancer that are eligible and willing to undergo standard of care (SOC) assessment, annually along with biopsies, bio-fluid collection. Participants will obtain genomic and histological evaluation on their biopsied samples. Study follows SOC collection with additional body fluid collection (blood, urine). Biopsy/surgery will not require additional sample collection

Research Team

Yoganand Balagurunathan, PhD

Principal Investigator

Moffitt Cancer Center

Julio Pow-Sang, MD

Principal Investigator

Moffitt Cancer Center

Eligibility Criteria

Inclusion Criteria

Patients diagnosed with prostate cancer at Moffitt or elsewhere, and have medical records and samples available.

Patients who had radical prostatectomy and may have had mpMR imaging, and have biological fluids available for research will be included. We follow the NCCN guidelines for including and following up with patients in the high-risk group.

You should be able to perform most of your usual activities without needing extra help or care.

Treatment Details

Participant Groups

Group I: Intermediate risk group (no-surgery) Experimental Treatment 1 Intervention

Participants diagnosed with pre-biopsy mpMRI.

Group II: High-risk group (surgery) Experimental Treatment 1 Intervention

Participants who had radical prostatectomy (RP) with (or with-out) mpMR imaging.

Who Is Running the Clinical Trial?

H. Lee Moffitt Cancer Center and Research Institute

Lead Sponsor

Trials

576

Recruited

145,000+